A Phase 1/2 interventional study of SRP-9004 in Limb-Girdle Muscular Dystrophy, Type 2D, sponsored by Sarepta Therapeutics, Inc.. Completed. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, dose escalation gene transfer therapy study evaluating the safety of SRP-9004 (patidistrogene bexoparvovec) via isolated limb infusion (ILI) administration in approximately 6 participants with LGMD2D.
47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.
This study's enrollment of 6 is below the median of 13 across 22 interventional studies indexed under Muscular Dystrophies, Limb-Girdle.
Browse Muscular Dystrophies, Limb-Girdle studies →Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-ambulant participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to a single limb on Day 0.
Genetic: SRP-9004
Participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to both limbs on Day 0.
Genetic: SRP-9004
Participants with LGMD2D will receive 1 high dose of SRP-9004 via ILI to both limbs on Day 0.
Genetic: SRP-9004
Isolated Limb Infusion (ILI)
Also known as: patidistrogene bexoparvovec
Number of Participants With Adverse Events (AEs).
An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered study drug related. An AE was considered serious if, in the view of the investigator or sponsor, it resulted in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Treatment-related Treatment Emergent Adverse Event (TEAE) is defined as an TEAE that was classified by the investigator as related to treatment.
Time frame: Up to 2 Years
Change From Baseline of the Distance Walked in 6 Minutes (6MWT)
The 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course in 6 minutes (timed), and the distance walked (in meters) was recorded.
Time frame: Baseline, Up to 2 Years
| Milestone | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 |
|---|---|---|---|
| Started | 1 | 3 | 2 |
| Received at least 1 dose of study drug | 1 | 3 | 2 |
| Completed | 1 | 3 | 2 |
| Not completed | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered study drug related. An AE was considered serious if, in the view of the investigator or sponsor, it resulted in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Treatment-related Treatment Emergent Adverse Event (TEAE) is defined as an TEAE that was classified by the investigator as related to treatment.
| Participants | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 |
|---|---|---|---|
| Adverse Events | 1 | 3 | 2 |
| Serious Adverse Events | 0 | 2 | 1 |
| Treatment Related TEAEs | 1 | 3 | 2 |
The 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course in 6 minutes (timed), and the distance walked (in meters) was recorded.
| Meters | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 |
|---|---|---|---|
| Change From Baseline of the Distance Walked in 6 Minutes (6MWT) | NA ± NA | -66.0 ± 77.78 | 29.0 ± NA |
Collected over Baseline up to 2 Years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1A: SRP-9004 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort 1B: SRP-9004 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 2: SRP-9004 | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Event | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 |
|---|---|---|---|
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/1 | 1/3 | 1/2 |
| MyoglobinuriaRenal and urinary disorders | 0/1 | 0/3 | 1/2 |
| Femur fractureInjury, poisoning and procedural complications | 0/1 | 1/3 | 0/2 |
| Event | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 |
|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 1/1 | 0/3 | 0/2 |
| Back painMusculoskeletal and connective tissue disorders | 1/1 | 0/3 | 1/2 |
| Procedural painInjury, poisoning and procedural complications | 0/1 | 3/3 | 2/2 |
| FatigueGeneral disorders | 0/1 | 1/3 | 2/2 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/1 | 0/3 | 2/2 |
| Catheter site haematomaGeneral disorders | 0/1 | 2/3 | 0/2 |
| InsomniaPsychiatric disorders | 0/1 | 0/3 | 1/2 |
| HypoaesthesiaNervous system disorders | 0/1 | 1/3 | 1/2 |
| Upper respiratory tract infectionInfections and infestations | 0/1 | 1/3 | 1/2 |
| Viral infectionInfections and infestations | 0/1 | 1/3 | 1/2 |
The full analysis set (FAS) included all participants who received at least 1 administration of SRP-9004 during the study.
| Age, Continuous(Years) | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 | Total |
|---|---|---|---|---|
| Mean | 49 ± NA | 10 ± 2.65 | 10 ± 2.83 | 16.5 ± 16.06 |
| Sex: Female, Male(Participants) | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 | Total |
|---|---|---|---|---|
| Female | 1 | 0 | 1 | 2 |
| Male | 0 | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 3 | 2 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1A: SRP-9004 | Cohort 1B: SRP-9004 | Cohort 2: SRP-9004 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 1 | 3 | 2 | 6 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Mar 2019, 49 months.
Results were first posted in Apr 2022, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophies, Limb-Girdle →